The effects of royal jelly for the adverse events of molecular target therapy for renal cancer patients

INTERVENTION: We examine this research using double‐blind method. We divide the patients into two groups, royal jelly group and placebo‐control group.The group of royal jelly patients take 2400mg /day royal jelly for 90 days. The patients of placebo group take encapsulated drugs 3 times a day for 90 days CONDITION: Renal cell carcinoma PRIMARY OUTCOME: The efficacy of royal jelly for the skin problem of the molecular target therapy. INCLUSION CRITERIA: 1. renal cell carcinoma patient 2. performance status 0‐1 3. WBC 3000/mm3 <= Neutro:1500/mm3 <= PLT:100,000/mm3 <= Hb:8g/dl <= AST and ALT:Upper limit 3 times or less T.Bil:1.5mg/dl => Crea:2.0mg/dl => FB:125mg/dl => 4. Those who can start this research within two weeks after resistration. 5. those who are 20 years and older 6. those who allow the participation for this study